Crystal-Induced Arthropathies

Ray T., 62, needs urate-lowering therapy for his gout, and he's also just survived a heart attack with stage 3b kidney disease already established. The disagreement is whether febuxostat's CARES-trial cardiovascular signal rules it out here, or whether allopurinol's own renal-dosing complexity makes it the harder drug to get right.

Denise K., 54, a hairdresser whose tophi are now deforming the hand she works with, needs pegloticase to have any real chance of working long-term. The disagreement is whether methotrexate or mycophenolate is the better immunomodulator partner to keep her body from destroying the drug before it can help her.

Harold M., 71, recently widowed and newly unsupervised in his own diabetes care, has a gout flare with every standard first-line option relatively contraindicated. The disagreement is whether an on-label IL-1 inhibitor or a cheaper off-label one is the right way through a flare that conventional therapy can't touch.

Aaron P., 41, training for his first marathon, had an incidental kidney stone turn up a strikingly high uric acid with no gout flare to show for it yet. The disagreement is whether treating hyperuricemia before any joint symptoms appear is genuinely justified, or whether it's treating a number instead of a disease.

Carla N., 58, has diabetes, heart failure, and gout all competing for the same next prescription. The disagreement is whether an SGLT2 inhibitor's incidental gout-risk-reduction should be the deciding factor over another guideline-supported option that does just as well for her heart.

Victor A., 57, has an acute gout flare arriving at the exact moment he's mid-course on clarithromycin, with kidney function already reduced. The disagreement is whether colchicine can be dosed carefully around a genuinely dangerous interaction, or whether the safer answer is not to use it at all.

Marcus D., 49, a kidney transplant recipient on azathioprine, isn't at his urate goal on allopurinol and can't simply raise a xanthine oxidase inhibitor that interacts dangerously with his transplant drug. The disagreement is whether adding probenecid or switching to uricosuric monotherapy is the safer way to close the gap.

Theo B., 46, a working guitarist whose tophi finally resolved on pegloticase, is running out of time before rising antibody levels make the drug stop working entirely. The disagreement is how to get him back onto oral therapy without losing the ground pegloticase already won.

Eugene R., a construction foreman with extensive tophaceous disease, and Nadia R., who has infrequent flares and no tophi, are both gout patients — but the case argues they don't belong on the same urate target. The disagreement is how much disease burden should determine how aggressively low that number needs to go.

Vivian S., 82, recently moved into assisted living, has a pseudogout flare arriving with kidney function too poor for either of the two usual first-line drugs. The disagreement is whether an intra-articular or systemic steroid is the safer route through a flare that's already closed off its most familiar options.

Walter G., 74, spent years treated for seronegative rheumatoid arthritis before the real diagnosis — chronic pseudo-rheumatoid CPPD — finally surfaced. The disagreement is which off-label DMARD, hydroxychloroquine or methotrexate, actually has the controlled evidence behind it once the wrong diagnosis is corrected.

Rosa D., 68, newly diagnosed with gout, needs flare prophylaxis to start allopurinol safely — and has a relative contraindication to all three standard options. The disagreement is which one to reach for anyway, and how honestly to frame a choice that's a compromise rather than a clean answer.